AAM Letter to FTC – Issues Impacting Generic Access and Competition
The Association for Accessible Medicines (AAM) has penned a letter (here) to the FTC, providing comments requested by that Agency relating to the Public Workshop held by FTC, Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics, held November 8, 2017 in Washington, D.C.. AAM (formerly the Generic Pharmaceutical Association [GPhA]) highlighted […]